Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lipson

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Pigment Cell & Melanoma Research|October 7, 2023
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)Alexander Z Wei, Lanyi N Chen, Marlana Orloff, et al.
Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Cancer Immunology Research|January 11, 2022
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in MelanomaMaryam Pourmaleki, Caitlin J Jones, Charlotte E Ariyan, et al.
Cancer Research Communications|September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor TherapyHoward L Li, Soren Charmsaz, Mari Nakazawa, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanomaMora Guardamagna, Sarah E Lochrin, James William Smithy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
The New England Journal of Medicine|April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaPaul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Science (New York, N.Y.)|June 11, 2021
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockadeSneha Berry, Nicolas A Giraldo, Benjamin F Green, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|September 12, 2022
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell CarcinomaNeil D Gross, David M Miller, Nikhil I Khushalani, et al.
Pigment Cell & Melanoma Research|October 7, 2023
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)Alexander Z Wei, Lanyi N Chen, Marlana Orloff, et al.
Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.
Journal for Immunotherapy of Cancer|January 20, 2025
Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockadeStephanie L Alden, Soren Charmsaz, Howard L Li, et al.
Cancer Immunology Research|January 11, 2022
Tumor MHC Class I Expression Associates with Intralesional IL2 Response in MelanomaMaryam Pourmaleki, Caitlin J Jones, Charlotte E Ariyan, et al.
Cancer Research Communications|September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor TherapyHoward L Li, Soren Charmsaz, Mari Nakazawa, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
International real-world study of combination immunotherapy sequences in metastatic melanomaMora Guardamagna, Sarah E Lochrin, James William Smithy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
The New England Journal of Medicine|April 20, 2016
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaPaul T Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Science (New York, N.Y.)|June 11, 2021
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockadeSneha Berry, Nicolas A Giraldo, Benjamin F Green, et al.
Pageof 21